SGR-3515 (WEE1 inhibitor)
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
SGR-3515 is a WEE1 inhibitor from Schrodinger. It is being developed for advanced solid tumors. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT06463340. The AI role named in the source is molecule design. Registry records: NCT06463340, Phase 1, recruiting, updated Aug 1, 2025. About the company, based in United States: Physics-based computational chemistry platform combined with machine learning, sold as software and used for partnered and internal discovery; launched the Bunsen agentic AI co-scientist in 2026. The latest dated source is from Aug 1, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Schrodinger
- Indication
- Advanced solid tumors
- Therapeutic area
- Oncology
- AI role
- Molecule design
- Phase in the source
- Phase 1, as of Aug 1, 2025
- Phase source
- Registry
- Board column
- Phase 1
AI evidence
AI source: Company
“the team trained project-specific machine learning (ML) models to predict time-dependent inhibition of CYP3A4 profiles”
Trial records
- NCT06463340 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
NCT06463340 first posted on ClinicalTrials.gov
-
ClinicalTrials.gov record: Phase 1
-
NCT06463340 record updated
Phase 1, Recruiting
About Schrodinger
Physics-based computational chemistry platform combined with machine learning, sold as software and used for partnered and internal discovery; launched the Bunsen agentic AI co-scientist in 2026.
Spot an error? Tell me and I'll fix it.